重组人粒细胞集落刺激因子临床应用管理中国专家共识(2026版)OA

Neutropenia is a common hematologic toxicity during antitumor therapy and can induce treatment delays,dose reduction,and even febrile neutropenia(FN),thereby causing poor prognosis.Human granulocyte-colony stimulating factor(G-CSF)has been widely used in the treatment of neutropenia,enabling early disease prevention,reduction in FN incidence,and improvement in antitumor efficacy.However,the standardization of G-CSF in clinical application still needs to be enhanced,and oncology pharmacists play a crucial role in its standardized application.Together with multiple professional committees,the Chinese Anti-Cancer Association Integrated Oncology Pharmacy Committee has developed the consensus to optimize G-CSF application,reduce medical costs,improve G-CSF pharmaceutical monitoring,and enhance patient benefits.